Physician profile
Angela Clemente
NPI 1144290602
$2,790.77
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $1,929 · 2020: $846 · 2021: $15.95.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $717.49 | 2019 | |
| Sunovion Pharmaceuticals INC. | $559.56 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $296.03 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $236.26 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $230.37 | 2019-2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $213.58 | 2019 | |
| Alkermes, INC. | $169.88 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $127.52 | 2019 | |
| Indivior INC. | $41.54 | 2020 | |
| Genentech, INC. | $39.95 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.23 | 2020 | |
| Neurocrine Biosciences, INC. | $26.03 | 2019 | |
| Adlon Therapeutics L.P. | $24.06 | 2020 | |
| Jazz Pharmaceuticals INC. | $17.13 | 2019 | |
| Eisai INC. | $16.82 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orexo US, INC. | $15.95 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.88 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.49 | 2020 |
Research and ownership
$1,078.19 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Clemente listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.